Business
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
Showcasing Disruptive Sublingual Drug Delivery Technology with Lead Program Targeting H2 2025 FDA Submission for Sublingual Aspirin Highlighting Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and a More-Rapid ED Medication ...
About this update from Aspire Biopharma Holdings, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Showcasing Disruptive Sublingual Drug Delivery Technology with Lead Program Targeting H2 2025 FDA Submission for Sublingual Aspirin","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Highlighting Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and a More-Rapid ED Medication","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Presentation and 1x1 Investor Meetings Scheduled Across the Two-Day Virtual Conference","length":86,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":338,"olType":false},{"type":"text","content":"ESTERO, FLORIDA / ACCESS Newswire / October 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending sublingual drug delivery technology, today announced that Kraig Higginson, Interim CEO of Aspire Biopharma will be presenting and participating in 1x1 meetings at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference.","length":438,"tagName":"p"},{"type":"text","content":"The presentation will feature updates on the company's pipeline progress and key milestones expected throughout the remainder of 2025 and early 2026. Aspire is focusing its pipeline on reformulating approved drugs for multi-billion-dollar markets by utilizing its disruptive, patent-pending sublingual delivery technology.","length":326,"tagName":"p"},{"type":"text","content":"Virtual Presentation - Wednesday, October 8th at 1:00 p.m. Eastern","length":66,"tagName":"p"},{"type":"text","content":"Virtual 1x1 Meetings - Wednesday, October 8th and Thursday, October 9th","length":71,"tagName":"p"},{"type":"text","content":"Format - Corporate presentations with fireside-style Q&A sessions proctored by Noble's analysts and bankers, along with scheduled 1×1 meetings with qualified investors","length":175,"tagName":"p"},{"type":"text","content":"Anticipated Milestones to be Discussed","length":38,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Sublingual High-dose Aspirin (Lead Program)","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"H2 2025: Request meeting with FDA to discuss 505(b)(2) pathway.","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"H2 2025: ...